XML 59 R44.htm IDEA: XBRL DOCUMENT v3.19.1
Income Taxes (Tables)
12 Months Ended
Mar. 31, 2019
Income Tax Disclosure [Abstract]  
Schedule of income from continuing operations before income taxes
 
Years Ended March 31,
(In millions)
2019
 
2018
 
2017
Income from continuing operations before income taxes
 
 
 
 
 
U.S.
$
1,512

 
$
1,175

 
$
5,772

Foreign
(902
)
 
(936
)
 
1,119

Total income from continuing operations before income taxes
$
610

 
$
239

 
$
6,891

Schedule of income tax expense (benefit) related to continuing operations
Income tax expense (benefit) related to continuing operations consists of the following:
 
Years Ended March 31,
(In millions)
2019
 
2018
 
2017
Current
 
 
 
 
 
Federal
$
(20
)
 
$
577

 
$
524

State
35

 
33

 
86

Foreign
152

 
205

 
122

Total current
167

 
815

 
732

 
 
 
 
 
 
Deferred
 
 
 
 
 
Federal
223

 
(767
)
 
767

State
44

 
17

 
164

Foreign
(78
)
 
(118
)
 
(49
)
Total deferred
189

 
(868
)
 
882

Income tax expense (benefit)
$
356

 
$
(53
)
 
$
1,614

Schedule of reconciliation between effective tax rate on income from continuing operations and statutory tax rate
The reconciliation of income tax expense (benefit) and the amount computed by applying the statutory federal income tax rate of 21% for 2019, 31.6% for 2018 and 35% for 2017 to the income before income taxes is as follows:
 
Years Ended March 31,
(In millions)
2019
 
2018
 
2017
Income tax expense at federal statutory rate
$
128

 
$
75

 
$
2,411

State income taxes net of federal tax benefit
70

 
50

 
153

Tax effect of foreign operations
(86
)
 
(146
)
 
(326
)
Unrecognized tax benefits and settlements
20

 
454

 
57

Non-deductible goodwill
357

 
585

 
106

Share-based compensation
4

 
(8
)
 
(54
)
Net tax benefit on intellectual property transfer
(42
)
 
(178
)
 
(137
)
Rate differential on gain from Change Healthcare Net Asset Exchange

 

 
(587
)
Impact of change in U.S. tax rate on temporary differences
(81
)
 
(1,324
)
 

Transition tax on foreign earnings
(5
)
 
457

 

Other, net (1)
(9
)
 
(18
)
 
(9
)
Income tax expense (benefit)
$
356

 
$
(53
)
 
$
1,614


(1)
Our effective tax rates were impacted by other favorable U.S. federal permanent differences including research and development credits of $7 million, $11 million and $14 million in 2019, 2018 and 2017.
Schedule of deferred tax balances
Deferred tax balances consisted of the following:
 
March 31,
(In millions)
2019
 
2018
Assets
 
 
 
Receivable allowances
$
70

 
$
58

Compensation and benefit related accruals
377

 
345

Net operating loss and credit carryforwards
885

 
811

Long-term contractual obligations

 
59

Other
216

 
279

Subtotal
1,548

 
1,552

Less: valuation allowance
(870
)
 
(751
)
Total assets
678

 
801

Liabilities
 
 
 
Inventory valuation and other assets
(2,016
)
 
(1,869
)
Fixed assets and systems development costs
(170
)
 
(158
)
Intangibles
(513
)
 
(644
)
Change Healthcare Equity Investment
(885
)
 
(814
)
Other
(34
)
 
(71
)
Total liabilities
(3,618
)
 
(3,556
)
Net deferred tax liability
$
(2,940
)
 
$
(2,755
)
 
 
 
 
Long-term deferred tax asset
$
58

 
$
49

Long-term deferred tax liability
(2,998
)
 
(2,804
)
Net deferred tax liability
$
(2,940
)
 
$
(2,755
)

Schedule of gross unrecognized tax benefits
The following table summarizes the activity related to our gross unrecognized tax benefits for the last three years:
 
Years Ended March 31,
(In millions)
2019
 
2018
 
2017
Unrecognized tax benefits at beginning of period
$
1,183

 
$
486

 
$
555

Additions based on tax positions related to prior years
78

 
47

 
7

Reductions based on tax positions related to prior years
(234
)
 
(124
)
 
(67
)
Additions based on tax positions related to current year
68

 
778

 
105

Reductions based on settlements
(13
)
 
(7
)
 
(113
)
Reductions based on the lapse of the applicable statutes of limitations
(25
)
 

 

Exchange rate fluctuations
(5
)
 
3

 
(1
)
Unrecognized tax benefits at end of period
$
1,052

 
$
1,183

 
$
486